Rand Paul Introduces Bill to Repeal Vaccine Liability Shield

Measure would amend 1986 law and allow civil lawsuits against vaccine manufacturers.

By yourNEWS Media Newsroom

Sen. Rand Paul, R-Ky., has introduced legislation aimed at ending federal liability protections for vaccine manufacturers, a legal safeguard that has been in place since 1986.

The proposal, co-sponsored by Sen. Mike Lee, R-Utah, was referred to the Senate Committee on Health, Education, Labor, and Pensions.

If enacted, the bill would amend the National Childhood Vaccine Injury Act of 1986 to remove the liability shield that largely protects vaccine manufacturers from product liability lawsuits. Under current law, most claims alleging vaccine-related injuries must be filed through a federal compensation program rather than pursued in civil court.

Paul said the legislation would increase accountability by permitting individuals to sue pharmaceutical companies if they believe they were harmed by a vaccine.

The National Childhood Vaccine Injury Act established the Vaccine Injury Compensation Program, which was designed to stabilize the vaccine market while providing a no-fault system for individuals seeking compensation for certain injuries.

According to data maintained by the Centers for Disease Control and Prevention, millions of adverse event reports have been submitted to the federal Vaccine Adverse Event Reporting System (VAERS) over time. VAERS allows healthcare providers, manufacturers, and members of the public to report health issues that occur after vaccination, though reports alone do not establish causation.

In addition, a study conducted in collaboration with the U.S. Department of Health and Human Services found that the nation’s primary vaccine adverse event reporting system captures fewer than 1 percent of adverse events. The findings were detailed in a final report available here.

Paul’s legislation comes amid ongoing debate over vaccine policy, liability protections, and the balance between public health safeguards and individual legal recourse. The measure’s prospects in the Senate remain uncertain.